解锁酶激活的秘密
Ross L Levine1, Stevan R Hubbard2
1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
概括
确定了Janus激酶 (JAK) 的全长结构,为开发向药物提供了新的见解. 这些结构信息对于设计更有效的JAK抑制剂疗法至关重要.
科学领域:
- 生物化学
- 结构生物学
- 药理学
背景情况:
- 简氏激酶 (JAKs) 是关键的细胞内信号酶,参与细胞因子信号通路.
- JAK信号的失调与各种自身免疫性疾病,炎症和癌症有关.
- 用小分子抑制剂向JAK已成为一种重要的治疗策略.
研究的目的:
- 确定一个特定的 Janus 激酶的全长结构.
- 为了解JAK激活和抑制提供详细的结构基础.
- 促进基于结构的新型JAK抑制剂的药物设计.
主要方法:
- 使用X射线结晶学来解析三维结构.
- 生物化学测定用于表征激酶活性和抑制剂结合.
- 计算模型被用来分析结构特征和相互作用.
主要成果:
- 全长Janus激酶的完整结构被阐明,揭示了关键的构造状态.
- 结构分析确定了对激酶活性和基质相互作用至关重要的特定区域.
- 已知抑制剂的结合方式被可视化,突出了改善药物设计的潜力.
结论:
- 确定全长的Janus激酶结构为药物开发提供了前所未有的原子级细节.
- 这种结构洞察力使得更有选择性和更强大的JAK抑制剂的合理设计成为可能.
- 这些发现为改善针对JAK介导疾病的治疗策略铺平了道路.
相关概念视频
The JAK-STAT Signaling Pathway
9.4K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.4K
MAPK Signaling Cascades
6.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.3K
cAMP-dependent Protein Kinase Pathways
6.7K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.7K
Amplifying Signals via Enzymatic Cascade
11.0K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
11.0K
Interactions Between Signaling Pathways
6.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
PI3K/mTOR/AKT Signaling Pathway
4.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.1K


